NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of solid tumors. References: Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009 Aug;9(8):537-49. doi: 10.1038/nrc2694. Review. PubMed PMID: 19629069.

纯度：≥98%

CAS：936446-61-6